Coherus BioSciences announced that the U.S. Food and Drug Administration, FDA, approved a single-dose, prefilled autoinjector presentation of UDENYCA, a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia. The UDENYCA autoinjector has a streamlined, easy-to-use design for use in both in-office and at-home settings of care. "The UDENYCA autoinjector represents the first innovation in the pegfilgrastim space in eight years and highlights Coherus’ commitment to developing innovative solutions that expand access and address the needs of patients undergoing cancer treatment," said Denny Lanfear, CEO of Coherus. Commercial availability of UDENYCA AI is planned for the second quarter of 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CHRS:
- Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
- Coherus BioSciences to Present at Upcoming Investor Conferences in March
- Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
- Coherus, Junshi announce final OS results of JUPITER-02 Phase 3 trial
- Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma